Thu, Dec 25, 2014, 9:43 PM EST - U.S. Markets closed for Christmas


% | $
Quotes you view appear here for quick access.

Google Inc. Message Board

baxterjames120 381 posts  |  Last Activity: 13 hours ago Member since: Dec 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    OMG Help Me.

    by snorkle_man Oct 6, 2014 4:48 PM
    baxterjames120 baxterjames120 Oct 6, 2014 5:20 PM Flag

    go hang yourself you pathetic liar. You are not funny.

  • How long it will take to develop an efficient production system “is unpredictable,” said Charles Arntzen, a plant biotechnology expert at Arizona State University. “This is a biological challenge and we are developing the rules and processes as we go along.”

    Caliber Biotherapeutics “is by far the largest facility in the world” for producing pharmaceuticals in tobacco plants, said Robert Kay, CEO of iBio Inc., a Newark, Delaware-based biotechnology company that owns one of the technologies used to make drugs in tobacco plants. “If anybody is going to produce this, it is almost axiomatic it has to be with Caliber involved.” Caliber didn’t immediately return a phone message left at its offices.

    While it is unclear what the best dose of ZMapp is, by some estimates, the 25 kilograms to 75 kilograms may translate into enough of the drug to treat several thousand patients.

    Kay estimates the production capacity of Caliber is about 100 kilograms of ZMapp per year, which he said could yield enough to treat 20,000 patients with the drug cocktail.

  • Grab your Hazmat suit. Ebola fears are spreading across the globe. Most people try to protect themselves. Investors look for ways to make money.

    There’s no cure for Ebola. Hopefully one is in the works. Currently, the best way to not die from Ebola is not getting it. That’s why a big winner is Lakeland Industries (LAKE). The company makes hazmat suits. The stock is one of the biggest winners on the market. Shares were up 274% this year before Tuesday’s trading began. Shares fell $7.57, or 26%, to $21.43 Tuesday as Ebola fears cooled a bit.

    And what’s a hazmat suit without a facemask? And that’s why Alpha Pro Tech (APT), a maker of protective gear such as facemasks, is hyperventilating. Shares are up 245% this year.

    But the end game is to wipe this disease off the face of the earth. There’s a long list of companies working on a cure. Hopes were high for shares of Chimerix (CMRX). The company’s Ebola treatment was given to the first patient in Dallas. But after the patient died, investors backed off. There’s a long list of public companies working on the problem. Companies like Tekmira (TKMR), Hemispherx (HEB), Newlink (NLNK), BioCryst (BRCX), Inovio (INO) and Sarepta (SRPT).

    And there are some other less obvious plays. The ZMapp drug is considered by some to be promising. It’s being developed by a private company called Leaf. It’s made from the tobacco plant. A unit of publicly traded Reynolds American (RAI) makes the drug.

    These are almost all speculative plays — and not appropriate for investors other than those that can tolerate great risk.

    Whether or not you make money on Ebola – let’s hope it gets cured. Soon.

    ebola, Buzz

  • Reply to

    New Revelations about non GAAP Reporting

    by james-hornback Nov 11, 2014 12:57 PM
    baxterjames120 baxterjames120 Nov 11, 2014 8:51 PM Flag

    That is one of the lamest bashes I have ever seen. Thanks for the entertainment.

  • bought a lot more at $1.98 and some more in the low $2's

  • baxterjames120 baxterjames120 Oct 21, 2014 8:25 AM Flag

    Yes- it is reiterated in an article just out on SA a few minutes ago. Thanks for rebutting AF's BS

    BARDA Task Order for ZMapp Production
    •Late Thursday evening, October 16, 2014 the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services issued a "task order" to three Centers for Innovation in Advanced Development and Manufacturing (CIADM) for proposals on large scale production of the experimental plant-made antibody drug, ZMapp.
    •The three CIADMs are public-private partnerships the members of which, in each case, include both corporations and universities. Only the three CIADMs, all of which have existing contracts with BARDA, are eligible to respond directly to this request from BARDA.
    •Although BARDA may have the legal authority to contract directly with individual corporations, no individual companies are eligible to respond to this task order.
    •However, none of the three CIADMs have the technology or facilities to manufacture antibodies in plants; and, therefore, the successful bidder will be required to subcontract the operational work under the task order to one or more companies with the necessary technology and/or facilities.
    •Any company manufacturing ZMapp in plants with the technology used for its non-human primate testing will require a U.S. patent license from iBio to avoid patent infringement. Other licenses may also be required.
    •iBio and Caliber Biotherapeutics have an existing agreement whereby iBio has provided an antibody product-specific commercial license to Caliber that can be augmented to provide freedom to operate in the manufacture of ZMapp. iBio has exclusive rights to certain patented technologies developed by its existing collaborator, Novici Biotech, that are proven to increase the expression yield of recombinant proteins and thereby increase the number of doses that can be manufactured in a given time frame.
    •BARDA was provided detailed information on these relationships, patents, and technologies during the drafting of the task order. iBio has been unable to comment in any further detail, except to provide the following background information and to observe that substantial, Ebola-specific work has been under way by several parties relevant to the emergency response to the Ebola outbreak, including iBio, since much earlier in its spread.

    Plant-Made Pharmaceutical Facilities

    There are four facilities in the U.S. capable of producing clinical quantities of plant-made proteins for vaccine or therapeutic purposes. These include
    •The world's largest plant-made pharmaceutical facility completed in March 2011, owned by Caliber Biotherapeutics LLC in Bryan, Texas, built largely with U.S. Department of Defense (NYSEARCA:DOD) funding following the success of iBioLaunch technology tests conducted for the DoD by Fraunhofer under license from iBio.
    •A pilot facility owned by the Fraunhofer USA Center for Molecular Biotechnology in Newark, Delaware and operated under license from iBio (configured primarily for vaccine products at the current time with limited total capacity for therapeutic antibody production).
    •A facility owned by Medicago (now a subsidiary of Mitsubishi) that was expanded with DoD funding in 2011 and is currently configured primarily for virus-like-particle (NYSE:VLP) vaccine manufacturing.
    •A facility owned by Kentucky Bioprocessing (now a subsidiary of a unit of R.J. Reynolds Tobacco Company) and configured for production of vaccines and therapeutics for phase 1 clinical trials (the capacity of which is now fully utilized for production of the ZMapp product for a phase 1 clinical trial)

    iBio has provided a license to Frauhofer and to Caliber for use of its technology for specific purposes. The existing Collaboration and License Agreement between iBio and Caliber provides rights to Caliber on a product-by-product basis in exchange for commercial consideration including royalties on end product sales. The first announced product designation under this agreement is an antibody-related protein for an oncology application.

    iBio has agreed, at the appropriate time, to augment its agreement with Caliber to provide Caliber with the right to manufacture the ZMapp antibodies under iBio patents.

    Any other manufacturer who desires to manufacture ZMapp antibodies in plants, as previously described in scientific publications by Mapp Biopharmaceutical, will require a commercial license from iBio, and iBio has offered to grant such licenses to parties designated by BARDA as appropriate.

    Technology for production of the ZMapp product
    •ZMapp antibodies, as produced and tested in non-human primates and as sought for emergency human use by BARDA, depend on access to the intellectual property of several companies.
    •The plant expression vector technology for antibody development in plants used by Mapp was obtained under a research license from Icon Genetics AG; however, issued U.S. patents owned by iBio dominate the Icon technology.
    •Therefore, to avoid patent infringement in the U.S. any manufacturer of the ZMapp product, unless the production process is degraded to using public domain methods alone, will require a commercial license from iBio.
    •Manufacturers of ZMapp may also require a commercial license from Icon for the use of that company's proprietary technology even though it falls under the claims of certain iBio patents.
    •To the extent specific transgenic host plants owned by Icon are used during manufacturing, a license from Icon may be required.
    •Of equal importance to the platform technology for antibody production is the urgent need to increase the expression yield of one or more of the antibody components of the ZMapp cocktail, and iBio has exclusive rights to technology proven uniquely effective by Novici Biotech LLC in significantly increasing protein expression yield without altering the structural or functional properties of the protein. This technology is directly and rapidly applicable to increasing the yield of ZMapp antibodies.

  • baxterjames120 baxterjames120 Oct 21, 2014 8:28 AM Flag

    If this is absolutely true- IBIO wins no matter what. Anyone using plant technology has to use IBIO technology and therefore royalties or some other manner of compensation to IBIO is a given

    Any company manufacturing ZMapp in plants with the technology used for its non-human primate testing will require a U.S. patent license from iBio to avoid patent infringement. Other licenses may also be required.
    •iBio and Caliber Biotherapeutics have an existing agreement whereby iBio has provided an antibody product-specific commercial license to Caliber that can be augmented to provide freedom to operate in the manufacture of ZMapp. iBio has exclusive rights to certain patented technologies developed by its existing collaborator, Novici Biotech, that are proven to increase the expression yield of recombinant proteins and thereby increase the number of doses that can be manufactured in a given time frame.
    •BARDA was provided detailed information on these relationships, patents, and technologies during the drafting of the task order. iBio has been unable to comment in any further detail, except to provide the following background information and to observe that substantial, Ebola-specific work has been under way by several parties relevant to the emergency response to the Ebola outbreak, including iBio, since much earlier in its spread.

  • They are not and will not make money from their business model.

  • baxterjames120 baxterjames120 Oct 17, 2014 6:06 PM Flag

    The iBioLaunch™ platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins. The plants are easily and reliably scaled-up in low cost, controlled growth facilities to produce large amounts of recombinant protein in the plant biomass. The technology is highly flexible having the capability to produce both biotherapeutics and vaccines. Advantages of the whole plant approach include lower operating and capital expenses compared to protein production using engineered microbial or animal cells in bioreactors. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required. Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed.

    The iBioLaunch technology platform addresses several multi-billion dollar markets. Its applicability to a broad range of product classes enables iBio to target global commercial collaborations in high-growth markets such as orphan biologics ($54.6 billion in 2009), biosimilars/bio-betters (~$80 billion worth of biologics sales will be susceptible to biosimilar competition, by 2013) and new proprietary biologics. The speed and superior economic scalability of the iBioLaunch™ technology make it the ideal platform for new personalized therapeutics as well as for vaccines ($32 billion in 2013).

  • The New York Times earlier reported that the federal government is looking to spur production of the experimental drug ZMapp used in the treatment of Ebola. The drug was developed by Mapp Biopharmaceuticals, a small company in San Diego.

    IBio has a collaboration agreement with Caliber Biotheraputics of Bryan, Texas on use of its technology.

    IBio, working with Fraunhofer Center for Molecular Biotechnology in Newark, has developed plant-based technology that can more rapidly bring vaccines to market. The system, that uses robotics and other technology, can rapidly grow plants that can be extracted for proteins used to make drugs, that include vaccines.

    The New York Times reported the government was talking with Caliber about producing the drug. The Times also reported talks were under way with drug companies that produce vaccines through non-plant methods that can churn out large amount of vaccines, but require long lead times.

    Tiny amounts of the Zmapp drug have run out, according to published reports. The drug is derived from tobacco plants, the Times reported. The drug has been used on a handful of patients, including an American, who survived.

    Last year IBio struck a deal with GE Healthcare to use its technology in building a plant-based vaccine plant in Brazil.

  • Asked if they can comment on there relationship with IBIO. They said they could not. Did not deny relationship and did not confirm. They did say they have used tobacco plants in the past for various drug experiments but would not comment on current activity. Anytime I hear "we can neither confirm nor deny…" That is a confirmation.

  • hanging tight- nothing has changed with the fundamentals from yesterday. Just profit taking and shorts having their day.

  • For the first time, Ebola is being treated using the Aethlon Hemopurifier (AHP) system. The method is a novel approach to treating viruses that filters them from the blood along with certain protein-based pathogens.

    The West African Ebola outbreak continues to extend its reach with cases now being diagnosed in the United States and Europe. Currently, there is no known treatment for the virus, which is lethal in a significant majority of cases. While treatments for the disease are being developed with some urgency, alternatives to conventional therapeutics are receiving marked interest as well.

    The AHP is one such therapeutic method that is being investigated at Frankfurt University Hospital, according to a press release from Aethlon. The patient is a Ugandan doctor who works for the World Health Organization. While ministering the ill in Sierra Leone, the doctor contracted the disease.

    "We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient," stated Aethlon founder and CEO Jim Joyce in the press release. "Details related to the patient's response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual."

    The AHP is currently being prepared for clinical trials in the U.S. under an investigational device exemption from the FDA. Initial tests started in India where it was used to treat human immunodeficiency virus (HIV) and Hepatitis C virus (HCV). Successful in vitro validation studies of the device’s effectiveness against Ebola Zaire were conducted by the Centers for Disease Control (CDC) and the United States Army Medical Research Institute for Infectious Diseases (USAMRIID).

    The AHP is said to have the capability to capture a broad spectrum of viral pathogens. In tests with HIV and HCV, it has been shown to reduce viral loads by up to 50 percent during a 4 hour treatment, according data published on the company website.

    The technology passes blood through its porous membrane media, and viral particles and fragments of these particles are captured by specific biomarkers attached to the media, according to a patent application filed by the company. These biomarkers may be lectins or other molecules that can be tailored to a specific disease.

    Filtration of blood as a way of eliminating or reducing circulating pathogens is the focus on many research groups that have developed a number of novel approaches. One such device has been termed the “biospleen,” because it filters pathogens like the organ it was named after, according to a recent article on Med Device Online. Another project has received significant grant money from the National Science Foundation for a microfluidic approach.

    Image Credit: “Ebola Virus Particles.

  • baxterjames120 by baxterjames120 Nov 10, 2014 8:33 AM Flag

    Ibio grants Caliber license for production of Antibodies targeting Ebola

  • There could be up to 10,000 new Ebola cases per week in Guinea, Liberia and Sierra Leone by the end of this year as the outbreak spreads, the World Health Organization warned Tuesday.

    And as the United States faces concerns over the first person to contract Ebola on American soil, the Centers for Disease Control and Prevention says it has a new plan to help hospitals handle the deadly virus.

    "For any hospital anywhere in the country that has a confirmed case of Ebola, we will put a team on the ground within hours," CDC Director Dr. Tom Frieden told reporters.

    Watch this video

    Dr. Sanjay Gupta answers: #EbolaQandA

    Watch this video

    How your hospital handles Ebola

    The new CDC Ebola response team will include experts in infection control, protective equipment and experimental therapies. A team like that, Frieden said, may have prevented a Dallas nurse from contracting the disease. The nurse was a member of the medical team that treated an Ebola patient who died last week.

    "I wish we had put a team like this on the ground the day the first patient was diagnosed. That might have prevented this infection," Frieden said. "But we will do that from this day onward with any case anywhere in the U.S."

    In addition to the many experts it sent to Dallas, Frieden said, the CDC "could have sent a more robust hospital infection control team and been more hands-on with the hospital from day one about exactly how this should be managed.

    "Ebola is unfamiliar. It's scary," said Frieden. "And getting it right is really, really important, because the stakes are so high."

    Speaking to reporters in Switzerland, WHO Assistant Director-General Dr. Bruce Aylward told reporters that the Ebola outbreak could get worse before it gets better.

    Already, it's gotten deadlier. The mortality rate has increased to 70%, he said.

    And by December, he said, there could be between 5,000 and 10,000 new cases weekly in West Africa.

    Compare those December projections to the latest figures. As of Tuesday morning, there were a total of 8,914 Ebola cases and 4,447 deaths reported to the WHO, Aylward said.

    Aylward told reporters that in 90 days, officials have a goal they're aiming for: They want to see the number of cases dropping from week to week.

    To start to decrease the rate of infection, the WHO says it hopes to isolate 70% of Ebola patients and have 70% of Ebola victim burials performed safely by December 1. Getting responders, facilities and plans in place to meet the goal will be very difficult, Aylward said.

    Missing the goal will mean that more people will die than should have and that even more resources will be needed because the infection rate will continue to climb, he said.

    Dallas nurse speaks out

    Days after authorities announced that a Dallas nurse had contracted Ebola, concerns in the United States have focused on a key question: Are people who are putting themselves in harm's way to care for Ebola victims receiving the training and equipment they need?

    "I've been hearing loud and clear from health-care workers from around the country that they're worried, that they don't feel prepared to take care of a patient with Ebola," Frieden said.

    Every hospital in the United States needs to be prepared to handle Ebola, he said, adding that the CDC will be stepping up training efforts.

    Watch this video

    Ebola: Proper medical protocols

    Watch this video

    Who is nurse Nina Pham?

    The Dallas nurse, Nina Pham, had cared for Liberian national Thomas Eric Duncan, who contracted Ebola in Liberia and died of the illness at Texas Health Presbyterian Hospital.

    "A single infection in a healthcare worker is unacceptable," Frieden said. "And what we're doing at this point is looking at everything we can do to minimize that risk so those that are caring for her do that safely and effectively."

    At least 76 health-care workers who may have come into contact with Duncan after he was hospitalized are now being monitored for symptoms of the disease, Frieden said.

    At the Dallas hospital, teams from the CDC are taking a number of steps to improve safety in handling Ebola, Frieden said. The steps include ensuring there's a site manager making sure protective equipment is put on and taken off correctly, enhancing training and limiting the number of staff providing care, Frieden said.

    Pham thanked supporters for sending kind wishes and prayers in a statement Tuesday, according to the Dallas hospital where she is being treated.

    "I am blessed by the support of family and friends and am blessed to be cared for by the best team of doctors and nurses in the world," she said.

    Infected nurse's assistant 'helping' as doctors treat her

    Health authorities in Spain said that a nurse's assistant who is the first person to contract Ebola in Europe in the current outbreak is still in serious condition but doing better.

    And even as Teresa Romero Ramos lies in a hospital bed, she's doing everything she can to take care of doctors, nurses and herself, said Dr. Marta Arsuaga, who is Romero's doctor and friend.

    "She is helping us to treat her. ... She was where I am now, so she knows what I have to do," Arsuaga said.

    Romero's case, like Pham's, has raised serious questions about how equipped hospitals are to cope with the Ebola outbreak.

    The European Centre for Disease Prevention and Control said Monday that the Madrid hospital treating Romero doesn't meet all the standards set for centers capable of Ebola care.

    And in a scathing letter, Javier Limon, Romero's husband, said she received only 30 minutes of training in putting on protective gear and called for the resignation of Madrid's regional health minister over how the case has been handled.

    Romero helped care for one of two Spanish missionaries who were brought back to Madrid for treatment after being infected with the virus in West Africa. Both men died of the illness.

    Besides treating Romero, Spanish authorities are monitoring 81 potential Ebola cases -- 15 in hospitals and 66 at home, according to the Spanish Ministry of Health. None of them is showing symptoms of Ebola, the ministry said.

    Romero is stable but remains in serious condition, Antonio Andreu, director of the Carlos III Hospital in Madrid, said at a news conference.

    A spokesman for a special committee created in Spain to keep people informed about Ebola told CNN that Spain will have a contagious diseases reference center in each of its regions.

    Police, firefighters and ambulance personnel, as well as hospital staff, will be trained to deal with Ebola cases.

    Andreu insisted that Spain's health care professionals have the situation under control. But he said more training will be given to health care workers and new guidelines will be prepared.

    "Ebola is not a problem of Spain. It is not a problem of the United States," he said. "It's a global problem

  • They are predicting 1,400,000 cases by January. It has already impacted Europe. Wait until we hear about cases in rural India and China. We are talking 3 BILLION PEOPLE IN THE BULLSEYE.

  • Still, the pharmaceutical industry has been slow to go green. (Several big drug companies contacted by Fortune had no comment on plant-based manufacturing other than to note they don’t use it.) That has left the exploration to others. Like the Pentagon. In 2009 the Defense Advanced Research Projects Agency, or DARPA, launched Blue Angel, a program that challenged three tobacco pharming facilities—among them, Kentucky BioProcessing and Texas-based Caliber Biotherapeutics (shown in the photo above)—to produce 10 million doses of flu vaccine in one month. The reward? Tens of millions in funding.

    Likewise, the process has drawn interest from nonprofits, which see its potential for addressing infectious-disease outbreaks and neglected illnesses. The Gates Foundation, for one, is working with iBio, one of the few publicly traded “plantibody” companies, to make low-cost vaccines for developing countries.

    As for the current West African outbreak of Ebola, pharming could perhaps offer a test case for containment. If ZMapp ultimately proves effective against the virus, experts say production could be ramped up to the necessary scale in months. And speed is critical in combating any contagion, says Maurice Moloney, who directs the agriculture, food, and health sector at Australia’s Commonwealth Scientific and Industrial Research Organization. Getting medication to people quickly, he says, “could save the world a lot of grief.” 

  • Not enough sellers to fill buyer demand!

528.77-1.82(-0.34%)Dec 24 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST